PsiloSterics is a drug discovery company focused on developing novel compounds for the targeted treatment of various neuropsychiatric disorders. We’ve created a proprietary portfolio of serotonin receptor agonists designed to target neurocircuit abnormalities in the brain that are responsible for difficult-to-treat disorders such as schizophrenia and depression. We have successfully identified several preclinical leads that have significantly improved characteristics (low/no hallucinogenic or cardiotoxic liability) when compared to other known serotonergic drugs. Psychoplastogenic drugs can address multiple conditions affecting large population groups representing sizable markets. However, many First-Gen natural and synthetic analogs are not optimized for therapeutic use. Our NCE platform will create safer and more accessible drugs that can be personalized on a per-indication, per-patient basis, and our strategy is already paying off with multiple lead programs identified via our data driven approach to drug discovery. We are collaborating with some of the world’s leading academic researchers and key opinion leaders in the serotonergic drug development space. Please reach out if you would like learn more about the work we are doing with our collaborators!